Compare WEAV & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | CATX |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 355.0M |
| IPO Year | 2021 | 2018 |
| Metric | WEAV | CATX |
|---|---|---|
| Price | $7.33 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $11.00 | ★ $12.11 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $1.96 |
| 52 Week High | $7.98 | $6.16 |
| Indicator | WEAV | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 63.04 | 34.74 |
| Support Level | $6.94 | $2.25 |
| Resistance Level | $7.33 | $2.96 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 56.43 | 1.69 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.